What do systematic reviews say?

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

The review found no eligible studies for this question.

• Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Intervention not reported

• Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intervention not reported

• Interventions for improving medication‐taking ability and adherence in older adults prescribed multiple medications 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Vitamin D plus calcium vs vitamin D

The review found no eligible studies for this question.

• Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin D plus calcium vs calcium

The review found no eligible studies for this question.

• Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CBT vs audiological care (tinnitus education and rehabilitation

• Cognitive behavioural therapy for tinnitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 410 participants
  Low

CBT vs TRT (directive counselling and bilateral masking)

• Cognitive behavioural therapy for tinnitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Low

CBT vs no treatment or waiting list

• Cognitive behavioural therapy for tinnitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 179 participants
  Very low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 506 participants
  Low

Sunitinib vs everolimus (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 288 participants
  Low

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 691 participants
  Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 544 participants
  Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 401 participants
  Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 157 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 394 participants
  Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 460 participants
  Moderate

Pazopanib vs placebo (targeted agent versus placebo)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 300 participants
  High

Intervention not reported

The review found no eligible studies for this question.

• Non‐nutritive sweeteners for diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found